Skip to content
View in the app

A better way to browse. Learn more.

Thailand News and Discussion Forum | ASEANNOW

A full-screen app on your home screen with push notifications, badges and more.

To install this app on iOS and iPadOS
  1. Tap the Share icon in Safari
  2. Scroll the menu and tap Add to Home Screen.
  3. Tap Add in the top-right corner.
To install this app on Android
  1. Tap the 3-dot menu (⋮) in the top-right corner of the browser.
  2. Tap Add to Home screen or Install app.
  3. Confirm by tapping Install.

Tirzepatide Slashes Obesity and Diabetes Risk

Featured Replies

Shows-the-different-mechanisms-of-action-of-Tirzepatide.ppm.png

 

 

A large three-year clinical trial found that weekly tirzepatide treatment dramatically reduced body weight and sharply cut the risk of developing type 2 diabetes in adults with obesity and prediabetes, offering immediate hope for patients facing both conditions. 

 

Obesity and prediabetes increase the likelihood of progressing to type 2 diabetes and are linked to serious health complications globally. In this trial, participants received once-weekly tirzepatide at doses of 5 mg, 10 mg, or 15 mg, or a placebo, over 176 weeks followed by a 17-week off-treatment period. 

 

Compared with placebo, tirzepatide led to marked and sustained weight loss at 176 weeks: participants lost far more body weight across all doses than those on placebo. Notably, rates of new type 2 diabetes diagnoses were much lower in tirzepatide groups (2.4 %) than in the placebo group (13.7 %). 

 

Researchers observed mostly gastrointestinal side effects during the early dose-escalation phase, but no new safety concerns emerged during the long-term follow-up. The outcomes underscore tirzepatide’s dual benefit—weight reduction and diabetes prevention—in a high-risk population. 

 

Experts say these results reinforce tirzepatide’s role as a potent therapeutic option that could shift treatment strategies for obesity and prediabetes, addressing two major public-health challenges simultaneously. 

 

Looking ahead, further real-world studies and longer follow-up in diverse populations will help clarify long-term impacts, optimal dosing strategies, and how best to integrate tirzepatide into broader metabolic disease care. 

 

Key Takeaways

• Tirzepatide produced significant, sustained weight loss in adults with obesity and prediabetes compared with placebo. 

 

• The risk of developing type 2 diabetes was markedly lower with tirzepatide versus placebo over three years. 

 

• No new long-term safety issues were identified beyond earlier reported gastrointestinal effects. 

 

Adapted From 

 

https://www.nejm.org/doi/full/10.1056/NEJMoa2410819

 

 

Create an account or sign in to comment

Recently Browsing 0

  • No registered users viewing this page.

Account

Navigation

Search

Search

Configure browser push notifications

Chrome (Android)
  1. Tap the lock icon next to the address bar.
  2. Tap Permissions → Notifications.
  3. Adjust your preference.
Chrome (Desktop)
  1. Click the padlock icon in the address bar.
  2. Select Site settings.
  3. Find Notifications and adjust your preference.